The prognostic immune nutritional index is a predictive biomarker in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide: Prognostic immune nutritional index and prostate adenocancer

Erkan Kayıkçıoglu; Eda Findos

doi:10.5281/zenodo.7331456

Authors

Erkan Kayıkçıoglu Suleyman Demirel University Faculty of Medicine, Department of Medical Oncology, Isparta, Turkey https://orcid.org/0000-0002-7401-5446
Eda Findos Suleyman Demirel University Faculty of Medicine, Department of Internal Medicine, Isparta, Turkey https://orcid.org/0000-0002-4489-1701

DOI:

https://doi.org/10.5281/zenodo.7331456

Keywords:

Abiraterone, castration resistant prostate cancer, enzalutamide, prognostic immune nutritional index

Abstract

Objective: To investigate the predictive efficacy of the geriatric nutritional risk index (GNRI) and novel prognostic immune nutritional index (PINI) in patients with metastatic castration–resistant prostate cancer (mCRPC) receiving abiraterone or enzalutamide.

Methods: We reviewed patients with mCRPC who received abiraterone or enzalutamide at the Suleyman Demirel University Hospital between 2015 and 2019. The GNRI was calculated using serum albumin and body mass index, with a GNRI <92.0 indicating poor nutritional status, and PINI was calculated using albumin and monocyte counts. The risk of survival was assessed using multivariate Cox-regression analysis.

Results: Eighty-three patients with mCRPC were included. In the low PINI group, it was 77.1% (PINI≤3.42). The median overall survival (OS) was 17 months in the low PINI group and 25 months in the high PINI group (p=0.00). ). The median OS was 21 and 25 months in the abiraterone and enzalutamide groups respectively; however the difference was not statistically significant (p=0.88). In a multivariate model, only low PINI was an independent risk factor for OS (Hazard Ratio [HR]=5.89, 95% Confidence Interval [CI]=2.07 to 16.7, p< 0.001).

Conclusion: In mCRPC patients treated with abiraterone or enzalutamide, a low PINI≤ 3.42 is associated with a shorter OS. The GNRI assessment for OS in patients with mCRPC treated with abiraterone or enzalutamide was not appropriate for our patients because only one patient had a low nutritional status (GNRI<92). There was no statistically significant difference in OS between the patients treated with abiraterone and those treated with enzalutamide.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

Chang LW, Hung SC, Li JR, Chiu KY, Yang CK, Chen CS, et al. Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. Front Pharmacol. 2020;11:601513.

Jung SH, Hao J, Shivakumar M, Nam Y, Kim J, Kim MJ, et al. Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index. Br J Cancer. 2022;126(11):1539-47.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-60.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-33.

Yamada K, Furuya R, Takita T, Maruyama Y, Yamaguchi Y, Ohkawa S, et al. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr. 2008;87(1):106-13.

Gu W, Zhang G, Sun L, Ma Q, Cheng Y, Zhang H, et al. Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. J Cachexia Sarcopenia Muscle. 2015;6(3):222-30.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-46.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-60.

Jung SH, Hao J, Shivakumar M, Nam Y, Kim J, Kim MJ, et al. Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index. Br J Cancer. 2022;126(11):1539-47.

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815-25.

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71(2):151-4.